Growth rate-corrected (GR) dose-response metrics across a panel of 71 breast cancer cell lines treated with a library of small molecule and antibody perturbagens. Dataset 1 of 4: Relative cell counts and normalized growth rate inhibition values across technical replicates. - Dataset (ID:20268)
Download: Excel (XLSX), Comma-separated (CSV)
| Cell | Clinical Subtype | Transcriptional Subtype | Small Molecule | Antibody | Perturbagen Target | Perturbagen Class | Perturbagen Concentration | Perturbagen Conc Unit | Biological Replicate ID | Relative Cell Count | Normalized Growth Rate Inhibition Value | Nominal Division Rate |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| HCC1187 | TNBC | Basal A | Erlotinib | EGFR | ErbB | 13.3 | uM | 7432.091 | 0.6817 | 0.3751 | 1.0227 | |
| HCC1187 | TNBC | Basal A | Erlotinib | EGFR | ErbB | 66.7 | uM | 7432.091 | 0.5242 | 0.0636 | 1.0227 | |
| HCC1187 | TNBC | Basal A | Erlotinib | EGFR | ErbB | 0.000171 | uM | 7433.09 | 1.0833 | 1.1980 | 0.8477 | |
| HCC1187 | TNBC | Basal A | Erlotinib | EGFR | ErbB | 0.000853 | uM | 7433.09 | 1.0775 | 1.1842 | 0.8477 | |
| HCC1187 | TNBC | Basal A | Erlotinib | EGFR | ErbB | 0.00427 | uM | 7433.09 | 1.0421 | 1.0996 | 0.8477 | |
| HCC1187 | TNBC | Basal A | Erlotinib | EGFR | ErbB | 0.0213 | uM | 7433.09 | 1.0170 | 1.0401 | 0.8477 | |
| HCC1187 | TNBC | Basal A | Erlotinib | EGFR | ErbB | 0.107 | uM | 7433.09 | 1.0245 | 1.0579 | 0.8477 | |
| HCC1187 | TNBC | Basal A | Erlotinib | EGFR | ErbB | 0.533 | uM | 7433.09 | 0.9527 | 0.8889 | 0.8477 | |
| HCC1187 | TNBC | Basal A | Erlotinib | EGFR | ErbB | 2.67 | uM | 7433.09 | 0.9996 | 0.9991 | 0.8477 | |
| HCC1187 | TNBC | Basal A | Erlotinib | EGFR | ErbB | 13.3 | uM | 7433.09 | 0.8027 | 0.5432 | 0.8477 | |
| HCC1187 | TNBC | Basal A | Erlotinib | EGFR | ErbB | 66.7 | uM | 7433.09 | 0.6476 | 0.1979 | 0.8477 | |
| HCC1395 | TNBC | Basal B | Erlotinib | EGFR | ErbB | 0.000171 | uM | 7435.091 | 1.0051 | 1.0178 | 0.5716 | |
| HCC1395 | TNBC | Basal B | Erlotinib | EGFR | ErbB | 0.000853 | uM | 7435.091 | 0.9929 | 0.9753 | 0.5716 | |
| HCC1395 | TNBC | Basal B | Erlotinib | EGFR | ErbB | 0.00427 | uM | 7435.091 | 0.9929 | 0.9753 | 0.5716 | |
| HCC1395 | TNBC | Basal B | Erlotinib | EGFR | ErbB | 0.0213 | uM | 7435.091 | 0.9469 | 0.8180 | 0.5716 | |
| HCC1395 | TNBC | Basal B | Erlotinib | EGFR | ErbB | 0.107 | uM | 7435.091 | 0.9552 | 0.8460 | 0.5716 | |
| HCC1395 | TNBC | Basal B | Erlotinib | EGFR | ErbB | 0.533 | uM | 7435.091 | 0.9520 | 0.8350 | 0.5716 | |
| HCC1395 | TNBC | Basal B | Erlotinib | EGFR | ErbB | 2.67 | uM | 7435.091 | 0.9331 | 0.7719 | 0.5716 | |
| HCC1395 | TNBC | Basal B | Erlotinib | EGFR | ErbB | 13.3 | uM | 7435.091 | 0.8207 | 0.4154 | 0.5716 | |
| HCC1395 | TNBC | Basal B | Erlotinib | EGFR | ErbB | 66.7 | uM | 7435.091 | 0.7155 | 0.1135 | 0.5716 | |
| HCC1395 | TNBC | Basal B | Erlotinib | EGFR | ErbB | 0.000171 | uM | 7436.091 | 1.0377 | 1.0601 | 1.2489 | |
| HCC1395 | TNBC | Basal B | Erlotinib | EGFR | ErbB | 0.000853 | uM | 7436.091 | 1.0042 | 1.0067 | 1.2489 | |
| HCC1395 | TNBC | Basal B | Erlotinib | EGFR | ErbB | 0.00427 | uM | 7436.091 | 1.0539 | 1.0858 | 1.2489 | |
| HCC1395 | TNBC | Basal B | Erlotinib | EGFR | ErbB | 0.0213 | uM | 7436.091 | 1.0256 | 1.0408 | 1.2489 | |
| HCC1395 | TNBC | Basal B | Erlotinib | EGFR | ErbB | 0.107 | uM | 7436.091 | 1.0120 | 1.0192 | 1.2489 |